Indexed metadata
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, Joachim Sieper, Pentti Järvinen, Lai-Shan Tam, Carlo Salvarani, Tae-Hwan Kim, Alan Solinger, Yakov Datsenko, Chandrasena Pamulapati, Sudha Visvanathan, David B Hall, Stella Aslanyan, Paul Scholl, Steven J Padula
Source record
Source: Crossref
Published: Sep 1, 2018
DOI: 10.1136/annrheumdis-2018-213328
Open original source ↗Evidence graph
No public relationships recorded yet.
Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.